Galera Therapeutics, INC. (GRTX) — 10-Q Filings

10-Q Filings (6)

• Galera Narrows Losses, Pivots to Breast Cancer After Asset Sale — Nov 13, 2025 Risk: high
  Galera Therapeutics, Inc. (GRTX) reported a net loss of $1.388 million for the three months ended September 30, 2025, a significant improvement from the $5.581
• Galera Narrows Losses Amid Strategic Pivot, Faces Going Concern Doubt — Aug 13, 2025 Risk: high
  Galera Therapeutics, Inc. (GRTX) reported a net loss of $1.075 million for the three months ended June 30, 2025, a significant improvement from the $4.064 milli
• Galera Therapeutics Files Q1 2025 10-Q — May 15, 2025 Risk: medium
  Galera Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition, including details on common stoc
• Galera Therapeutics Files Q3 2024 10-Q — Dec 13, 2024 Risk: medium
  Galera Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial information and business operations for the thir
• Galera Therapeutics Files Q2 2024 10-Q — Aug 14, 2024 Risk: medium
  Galera Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business activi
• Galera Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 13, 2024 Risk: medium
  Galera Therapeutics, Inc. (GRTX) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Galera Therapeutics, Inc. filed a 10-Q report for the period endi

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX